Market Cap (In AUD)
31.96 Million
Revenue (In AUD)
4.45 Million
Net Income (In AUD)
-4.5 Million
Avg. Volume
1.03 Million
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.055-0.18
- PE
- -
- EPS
- -
- Beta Value
- 0.778
- ISIN
- AU0000023822
- CUSIP
- Q0343V109
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.
- Employee Count
- -
- Website
- https://www.ampliatx.com
- Ipo Date
- 2014-01-12
- Details
- Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
More Stocks
-
300969NINGBO HENGSHUAI Co., LTD.
300969
-
LREN3Lojas Renner S.A.
LREN3
-
JACO
-
BEGRBE Group AB (publ)
BEGR
-
605098
-
BIOQBioqual, Inc.
BIOQ
-
MMNNFMunters Group AB (publ)
MMNNF
-
BNDSFBanco de Sabadell, S.A.
BNDSF